左西孟旦对扩张型心肌病失代偿患者N末端B型脑钠肽前体及心功能的影响

Effect of levosimendan on N-terminal B-type brain natriuretic peptide and cardiac function in patients with dilated cardiomyopathy decompensation

目的探讨左西孟旦治疗扩张型心肌病(DCM)失代偿患者血浆N末端B型脑钠肽前体(NT-proBNP)表达变化及心功能的影响。方法 56例DCM失代偿患者,随机分为对照组(31例)和治疗组(25例)。对照组采用常规治疗,治疗组在常规治疗基础上加用左西孟旦治疗,比较两组疗效。结果治疗组患者有效23例,有效率为92.0%,对照组患者有效27例,有效率为87.1%,两组有效率比较差异无统计学意义(χ~2=0.348,P>0.05)。治疗后,治疗组NT-proBNP浓度显著低于对照组,左心室射血分数(LVEF)高于对照组,差异具有统计学意义(P<0.05),两组左室舒张末内径比较,差异无统计学意义(P>0.05)。结论左西孟旦可有效改善DCM失代偿患者症状,进一步降低患者血浆NT-proBNP浓度和改善心脏收缩功能,值得借鉴。

Objective To investigate the effect of levosimendan on N-terminal B-type brain natriuretic peptide （NT-proBNP） and cardiac function in patients with dilated cardiomyopathy （DCM） decompensation. Methods A total of 56 DCM decompensation patients were randomy divided into control group （31 cases） and treatment group （25 cases）. The control group received conventional therapy, and the treatment group received levosimendan on the basis of conventional therapy. Efficacy in two groups was compared. Results The treatment group had 23 effective cases, accounting for 92.0%, and the control group had 27 effective cases, accounting for 87.1%. Their difference had statistical significance （X2=0.348, P〉0.05）. After treatment, the treatment group had obviously lower NT-proBNP concentration than the control group and higher left ventricular ejection fraction （LVEF） than the control group. Their difference had statistical significance （P〈0.05）. Both groups had no statistically significant difference in left ventricular end diastolic diameter （P〉0.05）. Conclusion Levosimendan can effectively improve the symptoms of DCM decompensation, and further reduce the plasma NT-proBNP concentration and improve cardiac systolic function. So it is worth learning.